This is the CEORoadshow “Biotech Spotlight” series where we interview veteran biotech investors, thought leaders and leading CEOs to discuss their insights and opinions about the current trends in biotech and healthcare.
Today’s segment focuses on the growing market opportunities in Immunotherapeutics and features Generex Biotechnology subsidiary NuGenenerex Immuno-Oncology.
According to the report from Zion Market Research, the global immunotherapy drugs market was valued at approximately $38.4 billion in 2018 and is expected to generate around $330.4 billion by 2025, at a CAGR of around 13.24% between 2019 and 2025.”
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient-centric care from rapid diagnosis through the delivery of personalized therapies.
They trade under ticker GNBT.
NuGenerex Immuno-Oncology (formerly Antigen Express) is developing novel immunotherapy & vaccine formulations based upon the Company’s li-Key hybrid peptides and li-Suppression technology. NuGenerex has a pipeline of immunotherapeutics that spans multiple therapeutic areas including oncology, infectious diseases, and autoimmune disorders.
In today’s discussion panel we are joined by Generex’s Chief Medical Officer and Chief Scientific Officer, Dr. Jason Terrell, as well as Richard Purcell, Senior Vice President of Research & Drug Development for Generex.
Dr. Terrell has held multiple senior leadership positions in the biotechnology industry with a strong background in clinical pathology and translational medicine. He is skilled in all aspects of medical product commercialization, from the technical sciences of research and development to the challenges of financing operations and accessing the capital markets. His primary research interests include epigenetics/nucleosomics, neoantigen/biomarker discovery, cancer metabolism, and novel drug delivery systems.
Mr. Purcell has managed a consulting practice, DNA Healthlink, Inc. advising emerging biopharmaceutical and technology companies on new business strategy, operations management, and clinical development of novel compounds. He oversees strategic planning, business development, clinical operations, R&D, and M&A for Generex.
About Generex Biotechnology Corp.
Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.
CEORoadshow.com is committed to providing our readers with useful information on publicly traded companies. CEORoadshow.com sometimes contracts with third parties or publicly traded companies and receives compensation from them in the form of cash and sometimes restricted securities as payment for publishing information and opinions about the company and the trading market for their securities. CEORoadshow.com content should not be considered to be independent publications concerning the company.
Neither CEOROADSHOW.COM or any of its principals currently own or plan to own within 72 hours of publication any shares of the stocks mentioned in this video. For a full disclaimer please visit, CEOROADSHOW.COM/disclaimer.
CEOROADSHOW content and productions are based on data obtained from sources we believe to be reliable but are not guaranteed as to the accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in CEOROADSHOW content and productions, or other investor relations materials and presentations are subject to change. Neither CEOROADSHOW nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. All data and information are provided for informational or entertainment purposes only. CEOROADSHOW is not a registered broker-dealer or a registered investment advisor.